Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who fully understand the study and are willing to sign a consent form agreeing to take part
- People who have been diagnosed with a condition called Large Granular Lymphocytic Leukaemia (LGLL)
- People of any gender who are 18 years of age or older
- People who have either never been treated for LGLL, were not adequately treated before, did not respond well enough to previous treatment, or whose condition came back after treatment that did not include methotrexate or thalidomide
- People whose LGLL is causing at least one of the following problems: very low white blood cell counts or repeated infections; low red blood cell levels or a need for regular blood transfusions; very low platelet counts; an autoimmune disease that needs treatment; a noticeably enlarged spleen causing symptoms; severe symptoms such as unexplained fever above 38°C, night sweats, or losing 10% or more of body weight within six months; or high blood pressure in the lungs
- People with a general health and activity level rated as reasonably functional (rated 0–2 on a standard medical scale used in clinical trials)
- People whose doctors expect them to survive for at least 6 months
Who may not be able to join:
- People who are unable to understand or follow the study procedures
- People who have been diagnosed with or treated for any cancer other than LGLL in the past five years
- People whose liver or kidney function is significantly reduced for reasons unrelated to their LGLL (confirm specific thresholds with the trial site)
- People with other serious medical conditions that could interfere with the study, such as uncontrolled diabetes, stomach ulcers, or serious heart or lung disease — the treating doctor at the trial site would assess this
- People whose assessment for blood clot risk comes back as "high risk" on a specific scoring tool used in this trial (confirm with trial site)
- People with a known history of HIV infection, currently active Hepatitis B virus (HBV) infection, or any active and uncontrolled infection currently being treated with intravenous antibiotics — note that people who had active HBV but successfully brought it under control with anti-HBV treatment may still be considered, provided they continue adequate treatment
- People who have had major surgery (not including lymph node biopsy) within the past 14 days, or who are expected to need major surgery during the treatment period
- People who are pregnant, breastfeeding, or of childbearing age and not using contraception
- People with a known allergy or sensitivity to any of the drugs or ingredients used in this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shuhua Yi, Doctor, Institute of Hematology & Blood Diseases Hospital, China
Phone: 86-22-23909106
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.